title: Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
authors.affiliation: Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Floris H
authors.initials: FH
authors.lastname: Groenendijk
authors.affiliation: Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Elisabeth E
authors.initials: EE
authors.lastname: Fransen van de Putte
authors.affiliation: Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Bas W G
authors.initials: BW
authors.lastname: van Rhijn
authors.affiliation: Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: René
authors.initials: R
authors.lastname: Bernards
authors.affiliation: Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.
authors.forename: Michiel S
authors.initials: MS
authors.lastname: van der Heijden
mesh_terms: D006801:Humans; D009154:Mutation; D020360:Neoadjuvant Therapy; D001749:Urinary Bladder Neoplasms